Work

A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic

Year: 2020

Type: article

Source: The Lancet Oncology

DOI: 10.1016/s1470-2045(20)30339-9

Authors: Crescens Tiu, Rajiv Shinde, Christina Yap, Bindumalini Rao Baikady, Udai Banerji, Anna R Minchom, Johann S de Bono, Juanita S Lopez

Institutions: Institute of Cancer Research, Royal Marsden Hospital, Royal Marsden NHS Foundation Trust

Language: English

Topic: COVID-19 and healthcare impacts

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: AstraZeneca, Bayer, Novartis, Cancer Research UK, National Institute for Health and Care Research, Astellas Pharma, Janssen Biotech

Awards: Translational proteomics to understand and overcome drug resistance to targeted anticancer drugs in KRAS and PIK3CA driven cancers, G3601372966, NIHR Senior Investigator Award, G662952953

OpenAlex ID: W3037539665

FWCI: 0.361

Cites:

Cited by: 4

Related to: 10